Annovis Bio News

H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30

H.C. Wainwright analyst Ram Selvaraju maintains $Annovis Bio(ANVS.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 43.6%

Moomoo NewsJul 17 12:38 ET · Ratings

Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion

TipRanksJul 17 12:27 ET

Express News | HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target

BenzingaJul 17 06:35 ET

Annovis Bio Says US FDA Approved Use of Neurodegeneration Drug Buntanetap in Crystalline Form

Annovis Bio (ANVS) said Tuesday that the US Food and Drug Administration has granted the company approval to use a new crystalline form of its neurodegeneration drug buntanetap in future clinical

MT NewswiresJul 16 08:39 ET

Express News | Annovis Bio Granted FDA Approval To Transition To New Crystal Form Of Buntanetap

BenzingaJul 16 08:00 ET

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

Tue, 16 Jul 2024MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug

Annovis BioJul 16 00:00 ET

Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Morgan

BenzingaJul 11 08:47 ET

H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Raises Target Price to $30

H.C. Wainwright analyst Ram Selvaraju maintains $Annovis Bio(ANVS.US)$ with a buy rating, and adjusts the target price from $23 to $30.According to TipRanks data, the analyst has a success rate of 39.

Moomoo NewsJul 11 08:31 ET · Ratings

Buy Rating Affirmed: Promising Buntanetap Phase 3 Results and Increased Approval Probability Boost Annovis Bio's Price Target

TipRanksJul 11 07:55 ET

HC Wainwright & Co. Maintains Buy on Annovis Bio, Raises Price Target to $30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio with a Buy and raises the price target from $23 to $30.

Analyst UpgradesJul 11 07:45 ET

Annovis Bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 147.12% HC Wainwright & Co. $23 → $30 Maintains Buy 07/02/2024 451.89% Rodman & Renshaw $67 → $

BenzingaJul 11 07:43 ET

Express News | Annovis Bio, Inc. : H.c. Wainwright Raises Target Price to $30 From $23

ReutersJul 11 07:37 ET

Annovis Bio Raises $7 Million From Warrant Exercises

TipRanksJul 10 16:28 ET

Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55

BenzingaJul 10 13:18 ET

Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating

Maxim Group analyst Jason McCarthy maintains $Annovis Bio(ANVS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 23.0% and a total average return of -22.6% over

Moomoo NewsJul 9 14:32 ET · Ratings

Maxim Group Sticks to Its Hold Rating for Annovis Bio (ANVS)

TipRanksJul 9 13:35 ET

Express News | Annovis Bio Shares Resume Trade

BenzingaJul 9 09:39 ET

Express News | Annovis Shares Halted On Circuit Breaker To Downside

BenzingaJul 9 09:35 ET

Express News | NYSE Halt Annovis Bio Ord Add Info Lst $13.950000

ReutersJul 9 09:34 ET

Press Release: Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-

Dow JonesJul 9 08:00 ET